NS-11394 structure.png
  • 2-(3-[5-(2-hydroxypropan-2-yl)benzimidazol-1-yl]phenyl)benzonitrile
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass353.425 g·mol−1
3D model (JSmol)
  • N#Cc2ccccc2-c(ccc3)cc3-n1cnc(c4)c1ccc4C(C)(C)O
  • InChI=1S/C23H19N3O/c1-23(2,27)18-10-11-22-21(13-18)25-15-26(22)19-8-5-7-16(12-19)20-9-4-3-6-17(20)14-24/h3-13,15,27H,1-2H3 ☒N
 ☒NcheckY (what is this?)  (verify)

NS-11394 is a drug which acts as a subtype-selective positive allosteric modulator at GABAA receptors, with selectivity for the α3 and α5 subtypes.[1][2] It has been researched as an analgesic for use in chronic or neuropathic pain.[3]


  1. ^ Munro G, Lopez-Garcia JA, Rivera-Arconada I, Erichsen HK, Nielsen EØ, Larsen JS, Ahring PK, Mirza NR (December 2008). "Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 969–81. doi:10.1124/jpet.108.144568. PMID 18791060. S2CID 36490884.
  2. ^ Mirza NR, Larsen JS, Mathiasen C, Jacobsen TA, Munro G, Erichsen HK, Nielsen AN, Troelsen KB, Nielsen EØ, Ahring PK (December 2008). "NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 954–68. doi:10.1124/jpet.108.138859. PMID 18791063. S2CID 206499795.
  3. ^ Munro G, Ahring PK, Mirza NR (September 2009). "Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets". Trends in Pharmacological Sciences. 30 (9): 453–9. doi:10.1016/j.tips.2009.06.004. PMID 19729210.